Log in
NASDAQ:SNOA

Sonoma Pharmaceuticals Stock Forecast, Price & News

$8.62
-0.51 (-5.59 %)
(As of 09/22/2020 12:00 AM ET)
Add
Compare
Today's Range
$8.12
Now: $8.62
$9.18
50-Day Range
$6.49
MA: $7.85
$9.55
52-Week Range
$3.33
Now: $8.62
$19.60
Volume76,652 shs
Average Volume416,394 shs
Market Capitalization$17.41 million
P/E RatioN/A
Dividend YieldN/A
Beta0.85
Sonoma Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and markets solutions for the treatment of chronic skin conditions and advanced tissue care in the United States and internationally. The company offers Levicyn, a hypochlorous acid (HOCl) based prescription product to manage and relieve burning, itching, and pain experienced with various types of dermatoses; Celacyn gel, a product indicated to promote healing through the management of new and old scars resulting from surgical procedures and trauma wounds or burns; SebuDerm, a product indicated to manage and relieve the burning, itching, pain, and distraction associated with seborrhea and seborrheic dermatitis; and Ceramax, a Lipogrid based skin barrier cream indicated to relieve and manage the burning and itching associated with various skin conditions. It also provides Mondoxyne, a doxycycline-based prescription oral tetracycline antibiotic used as a treatment for acne vulgaris; Acuicyn, a HOCl-based product indicated to relieve itch and inflammation while helping to keep areas around the eye clean; and Microcyn, a line of products designed to stimulate expedited healing by targeting various pathogens, as well as antibiotic-resistant strains that slow natural healing of wounds. In addition, the company offers MicrocynAH and MicrocynVS, which are HOCl-based solutions designed to relieve common symptoms of hot spots, scratches, skin rashes post-surgical sites, and irritated animal skin for healing; and Pediacyn, Epicyn, Gramaderm, and Microdacyn for dermatoses, scar management, and acne. The company was formerly known as Oculus Innovative Sciences, Inc. and changed its name to Sonoma Pharmaceuticals, Inc. in December 2016. Sonoma Pharmaceuticals, Inc. was incorporated in 1999 and is headquartered in Petaluma, California.
Read More
Sonoma Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.50 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:SNOA
CUSIPN/A
Phone800-759-9305

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$18.94 million
Book Value$4.90 per share

Profitability

Net Income$-2,950,000.00

Miscellaneous

Employees78
Market Cap$17.41 million
Next Earnings Date11/12/2020 (Estimated)
OptionableNot Optionable
$8.62
-0.51 (-5.59 %)
(As of 09/22/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive SNOA News and Ratings via Email

Sign-up to receive the latest news and ratings for SNOA and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Sonoma Pharmaceuticals (NASDAQ:SNOA) Frequently Asked Questions

How has Sonoma Pharmaceuticals' stock been impacted by Coronavirus?

Sonoma Pharmaceuticals' stock was trading at $4.80 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, SNOA shares have increased by 79.6% and is now trading at $8.62.
View which stocks have been most impacted by COVID-19
.

When is Sonoma Pharmaceuticals' next earnings date?

Sonoma Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, November 12th 2020.
View our earnings forecast for Sonoma Pharmaceuticals
.

How were Sonoma Pharmaceuticals' earnings last quarter?

Sonoma Pharmaceuticals Inc (NASDAQ:SNOA) posted its earnings results on Friday, July, 10th. The company reported ($1.26) earnings per share (EPS) for the quarter. The firm earned $4.58 million during the quarter. Sonoma Pharmaceuticals had a negative return on equity of 43.19% and a negative net margin of 12.42%.
View Sonoma Pharmaceuticals' earnings history
.

Are investors shorting Sonoma Pharmaceuticals?

Sonoma Pharmaceuticals saw a decrease in short interest during the month of August. As of August 14th, there was short interest totaling 36,700 shares, a decrease of 93.1% from the July 30th total of 532,600 shares. Based on an average trading volume of 1,110,000 shares, the short-interest ratio is currently 0.0 days. Approximately 1.8% of the shares of the company are short sold.
View Sonoma Pharmaceuticals' Short Interest
.

Who are some of Sonoma Pharmaceuticals' key competitors?

What other stocks do shareholders of Sonoma Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Sonoma Pharmaceuticals investors own include Inovio Pharmaceuticals (INO), VelocityShares Daily 2x VIX Short Term ETN (TVIX), Sorrento Therapeutics (SRNE), Bristol-Myers Squibb (BMY), Gilead Sciences (GILD), Amarin (AMRN), Pfizer (PFE), Tesla (TSLA), Nabriva Therapeutics (NBRV) and Verastem (VSTM).

Who are Sonoma Pharmaceuticals' key executives?

Sonoma Pharmaceuticals' management team includes the following people:
  • Mr. Frederick J. Sandford, CEO, Interim CFO & Director (Age 58)
  • Mr. Marc Umscheid, Chief Operating Officer (Age 50)
  • Dr. Robert Northey, Exec. VP of R&D (Age 62)
  • Mr. Bruce Thornton, Exec. VP of International Operations & Sales (Age 55)
  • Ms. Victoria Covel, Assistant Controller

What is Sonoma Pharmaceuticals' stock symbol?

Sonoma Pharmaceuticals trades on the NASDAQ under the ticker symbol "SNOA."

How do I buy shares of Sonoma Pharmaceuticals?

Shares of SNOA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Sonoma Pharmaceuticals' stock price today?

One share of SNOA stock can currently be purchased for approximately $8.62.

How big of a company is Sonoma Pharmaceuticals?

Sonoma Pharmaceuticals has a market capitalization of $17.41 million and generates $18.94 million in revenue each year. Sonoma Pharmaceuticals employs 78 workers across the globe.

What is Sonoma Pharmaceuticals' official website?

The official website for Sonoma Pharmaceuticals is www.sonomapharma.com.

How can I contact Sonoma Pharmaceuticals?

Sonoma Pharmaceuticals' mailing address is 645 MOLLY LANE SUITE 150, WOODSTOCK GA, 30189. The company can be reached via phone at 800-759-9305 or via email at [email protected]

This page was last updated on 9/23/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.